Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: A randomized, double-blind, placebo-controlled, crossover study

Pediatrics

Volumn 110, Issue 5, 2002, Pages 889-896

  Gravholt, Claus Højbjerg ^a   Naeraa, Rune Weis ^a   Brixen, Kim ^a,b   Kastrup, Knud William ^c   Mosekilde, Leif ^a   Jørgensen, Jens Otto Lunde ^a   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Body composition; Body mass index; DXA scan; Growth hormone treatment; glucose metabolism; IGF L; Insulin sensitivity

Indexed keywords

FOLLITROPIN; GLUCOSE; HUMAN GROWTH HORMONE; INSULIN; PLACEBO; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCONEOGENESIS; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEXUAL DEVELOPMENT; SHORT COURSE THERAPY; TURNER SYNDROME;

ADIPOSE TISSUE; ADOLESCENT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; BONE AND BONES; BONE DEVELOPMENT; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; TURNER SYNDROME;

EID: 0036843264     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.110.5.889     Document Type: Article

References (54)

1. Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner's syndrome: Beneficial effect on adult height. J Pediatr. 1998;132:319-324
2. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: Results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999;84:4607-4612
3. Jensen MB, Hermann AP, Hessov IB, Mosekilde L. Components of variance when assessing the reproducibility of body composition measurements using bio-impedance and the Hologic QDR-2000 DXA scanner. Clin Nutr. 1997;16:61-65
4. Abrahamsen B, Gram J, Hansen TB, Beck NH. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. Bone. 1995;16:385-390
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419
6. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470
7. Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 1995;5:169-176
8. Orskov H, Thomsen HG, Yde H. Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature. 1968;219:193-195
9. Lloyd B, Burrin J, Smythe P, Alberti KG. Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate. Clin Chem. 1978;24:1724-1729
10. Price PA, Nishimoto SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci U S A. 1980;77:2234-2238
11. Recommended methods for the determination of four enzymes in blood. Scand J Clin Lab Invest. 1974;33:291-306
12. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem. 1993;39:635-640
13. Ranke MB, Blum WF, Haug F, et al. Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinol. 1987;116:305-313
14. Saenger P, Schwartz E, Wiedemann E, Levine LS, Tsai M, New MI. The interaction of growth hormone, somatomedin and oestrogen in patients with Turner's syndrome. Acta Endocrinol. 1976;81:9-18
15. Wit JM, Massarano AA, Kamp GA, et al. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol. 1992;127:7-12
16. Massarano AA, Brook CG, Hindmarsh PC, et al. Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol. Arch Dis Child. 1989;64:587-592
17. Reiter JC, Craen M, Van Vliet G. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: Relation to body weight and adiposity. Acta Endocrinol. 1991;125:38-42
18. Foster CM, Borondy M, Markovs ME, Hopwood NJ, Kletter GB, Beitins IZ. Growth hormone bioactivity in girls with Turner's syndrome: Correlation with insulin-like growth factor I. Pediatr Res. 1994;35:218-222
19. Blethen SL, Albertsson Wikland K, Faklis EJ, Chasalow FI. Circulating growth hormone isoforms in girls with Turner's syndrome. J Clin Endocrinol Metab. 1994;78:1439-1443
20. Ishikawa M, Yokoya S, Tachibana K, et al. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. J Clin Endocrinol Metab. 1999;84:98-104
21. Ross JL, Long LM, Loriaux DL, Cutler GBJ. Growth hormone secretory dynamics in Turner syndrome. J Pediatr. 1985;106:202-206
22. Zadik Z, Landau H, Chen M, Altman Y, Lieberman E. Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. J Clin Endocrinol Metab. 1992;75:412-416
23. Gravholt CH, Frystyk J, Flyvbjerg A, Orskov H, Christiansen JS. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: Modulation by female sex steroids. Am J Physiol. 280:E308-E314, 2001
24. Gravholt CH, Veldhuis JD, Christiansen JS. Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: The impact of body composition, maximal oxygen uptake and treatment with sex hormones. Growth Horm IGF Res. 1998;8:289-298
25. Gravholt CH, Naeraa RW, Fisker S, Christiansen JS. Body composition and physical fitness are major determinants of the growth hormone-IGF axis aberrations in adult Turner syndrome, with important modulations by treatment with 17-beta-estradiol. J Clin Endocrinol Metab. 1997;82:2570-2577
26. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994;78:744-752
27. Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome. A cross-sectional study. J Clin Endocrinol Metab. 2002;87:2798-2808
28. Vestergaard P, Hermann AP, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: A cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab. 1999;84:2286-2290
29. Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab. 1993;76:861-866
30. Lanes R, Gunczler P, Paoli M, Weisinger JR. Bone mineral density of prepubertal age girls with Turner's syndrome while on growth hormone therapy. Horm Res. 1995;44:168-171
31. Bertelloni S, Cinquanta L, Baroncelli GI, Simi P, Rossi S, Saggese G. Volumetric bone mineral density in young women with Turner's syndrome treated with estrogens or estrogens plus growth hormone. Horm Res. 2000;53:72-76
32. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, et al. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial. Clin Endocrinol (Oxf). 2000;52:531-536
33. Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res. 1990;5:609-618
34. Marcus R, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab. 1990;70:519-527
35. Brixen K, Kassem M, Nielsen HK, Loft AG, Flyvbjerg A, Mosekilde L. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: A dose response study. J Bone Miner Res. 1995;10:1865-1874
36. Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab, 1996;81:3352-3359
37. Brixen K, Hansen TB, Hauge E, et al. Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: A 1-year, double-blind, randomized, placebo-controlled study. Bone Miner Res. 2000;15:293-300
38. Ikkos D, Luft R, Gemzell CA. The effect of human growth hormone in man. Lancet. 1958;1:720-721
39. Raben MS, Hollenberg CH. Effect of growth hormone on plasma fatty acids. J Clin Invest. 1959;38:484-488
40. Caprio S, Boulware S, Diamond M, et al. Insulin resistance: An early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab. 1991;72:832-836
41. Stoppoloni G, Prisco F, Alfano C, lafusco D, Marrazzo G, Paolisso G. Characteristics of insulin resistance in Turner syndrome. Diabetes Metab.1990;16:267-271
42. Gravholt CH, Nyholm B, Saltin B, Schmitz O, Christiansen JS. Muscle fiber composition and capillary density in Turner syndrome: Evidence of increased muscle fiber size related to insulin resistance. Diabetes Care. 2001;24:1668-1673
43. Larsson H, Daugaard JR, Kiens B, Richter EA, Ahren B. Muscle fiber characteristics in postmenopausal women with normal or impaired glucose tolerance. Diabetes Care. 1999;22:1330-1338
44. Heinze E, Schlickenrieder J, Holl RW, Ebert R. Reduced secretion of gastric inhibitory polypeptide in Turner patients with impaired glucose tolerance. Eur J Pediatr. 1991;150:339-342
45. Heinze E, Clark PMS, Hales CN, Orskov C, Ebert W, Holl RW, Reduced GIP contributes to altered insulin response following oral glucose in women with Turner syndrome. Diabetologia. 1993;36(suppl 1):A48-A48. Abstract 182
46. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG. Carbohydrate and lipid metabolism in Turner syndrome: Effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr. 1988;112:210-217
47. Caprio S, Boulware SD, Press M, et al. Effect of growth hormone treatment on hyperinsulinemia associated with Turner syndrome. J Pediatr. 1992;120:238-243
48. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study., Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab. 2000;85:769-775
49. Ranke MB, Pfluger H, Rosendahl W, et al. Turner syndrome: Spontaneous growth in 150 cases and review of the literature. Eur J Pediatr. 1983;141,:81-88
50. Phipps K, Barker DJ, Hales CN, Fall CH, Osmond C, Clark PM. Fetal growth and impaired glucose tolerance in men and women. Diabetologia. 1993;36:225-228
51. Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adren-arche - Normal variant or forerunner of adult disease? Endocr Rev. 2000;21:671-696
52. Larizza D, Cuccia M, Martinetti M, et al. Adrenocorticotrophin stimulation and HLA polymorphisms suggest a high frequency of heterozygosity for steroid 21-hydroxylase deficiency in patients with Turner's syndrome and their families. Clin Endocrinol (Oxf). 1994;40:39-45
53. Balducci R, Toscano V, Larizza D, et al. Effects of long-term growth hormone therapy on adrenal steroidogenesis in Turner syndrome. Horm Res. 1998;49:210-215
54. Gravholt CH, Naeraa RW. Reference values for body proportions and body composition in adult women with Turner's syndrome. Am J Med Genet. 1997;72:403-408